C. Lasset

J. Simard, D. Yannoukakos, J. Peyrat, 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

BRCA 1 Wild-Type Allele Modifies Risk of Ovarian Cancer in Carriers of BRCA 1 GermLine Mutations 1

J. Simard, D. Yannoukakos, J. Peyrat, 2003 .

IV.4 Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case—Control study

C. Lasset, V. Bonadona, H. Mignotte, 1998 .

Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21.

D E Goldgar, M. Papotti, F. Canzian, 2001, American journal of human genetics.

Non-metastatic childhood ependymomas.

C. Mottolese, E. Bouffet, C. Lasset, 1995, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Intensity‐dependent constitutional MLH1 promoter methylation leads to early onset of colorectal cancer by affecting both alleles

Z. Herceg, J. Saurin, A. Puisieux, 2011, Genes, chromosomes & cancer.

Breast Cancer Risk Associated with Estrogen Exposure and Truncating Mutation Location in BRCA1/2 Carriers

D. Stoppa-Lyonnet, P. Pujol, J. Fricker, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Breast Cancer Risk Associated with Estrogen Exposure and Truncating Mutation Location in BRCA 1 / 2 Carriers

D. Stoppa-Lyonnet, P. Pujol, J. Fricker, 2015 .

French women’s knowledge of and attitudes towards cervical cancer prevention and the acceptability of HPV vaccination among those with 14 – 18 year old daughters: a quantitative-qualitative study

P. Vanhems, F. Chauvin, C. Lasset, 2012, BMC Public Health.

Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.

G. Lenoir, O. Sinilnikova, C. Lasset, 2002, Journal of the National Cancer Institute.

Patients' characteristics and rate of Internet use to obtain cancer information.

Valérie Bonadona, Dominique Stoppa-Lyonnet, D. Stoppa-Lyonnet, 2006, Journal of public health.

Practices and opinions regarding HPV vaccination among French general practitioners: evaluation through two cross-sectional studies in 2007 and 2010

P. Vanhems, F. Chauvin, C. Lasset, 2014, International Journal of Public Health.

Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case‐control study

C. Granon, L. Mauriac, F. Chauvin, 1998, International journal of cancer.

Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing

M. Bihoreau, N. Servant, D. Stoppa-Lyonnet, 2018, International journal of cancer.

Integrated analysis highlights APC11 protein expression as a likely new independent predictive marker for colorectal cancer

Y. Drouet, N. Voirin, A. Viari, 2018, Scientific Reports.

Germline hMSH2and hMLH1 gene mutations in incomplete HNPCC families

J. Saurin, A. Puisieux, M. Ozturk, 1997, International journal of cancer.

Identification et prise en charge du syndrome HNPCC (hereditary non polyposis colon cancer). prédisposition héréditaire aux cancers du côlon, du rectum et de l'utérus

G. Thomas, P. Laurent-Puig, T. Frebourg, 2006 .

Mise au point Prédispositions héréditaires au cancer colorectal

G. Thomas, P. Laurent-Puig, C. Bonaïti‐pellié, 2005 .

Prédispositions héréditaires au cancer colorectal

G. Thomas, P. Laurent-Puig, C. Bonaïti‐pellié, 2005 .

Le syndrome HNPCC (hereditary non polyposis colon cancer) : identification et prise en charge

G. Thomas, P. Laurent-Puig, T. Frebourg, 2005 .

[Identification and management of HNPCC syndrome (hereditary non polyposis colon cancer), hereditary predisposition to colorectal and endometrial adenocarcinomas].

G. Thomas, P. Laurent-Puig, T. Frebourg, 2004, Bulletin du cancer.

[Comparison of 2 cisplatin and etoposide dosages in relapsing small cell lung cancer].

P. Fournel, C. Lasset, V. Trillet-lenoir, 1992, Bulletin du cancer.

New founder germline mutations of CDKN2A in melanoma‐prone families and multiple primary melanoma development in a patient receiving levodopa treatment

L. Thomas, G. Lenoir, A. Chompret, 2007, Genes, chromosomes & cancer.

Comparison of physicians' and cancer prone women's attitudes about breast/ovarian prophylactic surgery. Results from two national surveys

D. Stoppa-Lyonnet, J. Moatti, H. Sobol, 2004, Familial Cancer.

Disclosure to the family of breast/ovarian cancer genetic test results: patient's willingness and associated factors.

D. Stoppa-Lyonnet, H. Sobol, C. Lasset, 2000, American journal of medical genetics.

Four Years Analysis of Cancer Genetic Clinics Activity in France from 1994 to 1997: A Survey on 801 Patients

D. Stoppa-Lyonnet, Y. Bignon, H. Sobol, 2002, Disease markers.

Short-term risk of colorectal cancer in individuals with lynch syndrome: a meta-analysis.

Aung Ko Win, J. Mathews, Y. Drouet, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sporadic and epidemic community legionellosis: two faces of the same illness

P. Vanhems, C. Lasset, S. Pires-Cronenberger, 2007, European Respiratory Journal.

1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party.

T. Klingebiel, J. Zucker, F. Chauvin, 1997, European journal of cancer.

Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

Annette Lee, W. Chung, R. Nussbaum, 2018, Human mutation.

Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers

W. Chung, J. Benítez, R. Eeles, 2020, Breast Cancer Research.

Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial

J. Lemonnier, P. Pujol, J. Fricker, 2011, Familial Cancer.

Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort.

N. Voirin, G. Lenoir, O. Sinilnikova, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of anthracycline/taxane‐based neo‐adjuvant chemotherapy on triple‐negative breast cancer in BRCA1/BRCA2 mutation carriers

T. Petit, D. Stoppa-Lyonnet, J. Fricker, 2018, The breast journal.

Abstract 1442: Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype

N. Voirin, I. Treilleux, A. Puisieux, 2010 .

Evidence of a hereditary p53 syndrome in cancer‐prone families

M. Ozturk, Q. Wang, H. Sobol, 1996, International journal of cancer.

Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

W. Chung, P. Hall, V. Pankratz, 2013, PLoS Genetics.

BRCA2 mutations in hereditary breast and ovarian cancer in France.

R. Lidereau, G. Lenoir, S. Mazoyer, 1997, American journal of human genetics.

Endometrial carcinoma (EC) in women with breast cancer (BC)

C. Granon, L. Mauriac, F. Chauvin, 1997 .

Multivariate analysis of prognostic factors in adult patients with medulloblastoma. Retrospective study of 156 patients

C. Haie-meder, C. Lasset, C. Kerr, 1994, Cancer.

Tamoxifen and risk of endometrial cancer

C. Lasset, V. Bonadona, A. Brémond, 2001, The Lancet.

Risk of endometrial cancer in premenopausal women on tamoxifen

F. Chauvin, C. Lasset, V. Bonadona, 1998, The Lancet.

Which factors predict proposal and uptake of psychological counselling after BRCA1/2 test result disclosure?

D. Stoppa-Lyonnet, J. Fricker, A. Bouhnik, 2014, Psycho-oncology.

Novel biallelic mutations in MSH6 and PMS2 genes: gene conversion as a likely cause of PMS2 gene inactivation

J. Saurin, A. Puisieux, Qing Wang, 2007, Human mutation.

Interleukin-2 Therapy: Report on 129 Patients and Three Different Schedules

J. Blay, M. Favrot, C. Lasset, 1994 .

Male breast cancer in BRCA1 and BRCA2 mutation carriers

R. Nussbaum, D. Steinemann, F. Couch, 2018 .

A new hybrid record linkage process to make epidemiological databases interoperable: application to the GEMO and GENEPSO studies involving BRCA1 and BRCA2 mutation carriers

F. Révillion, Chloé-Agathe Azencott, N. Sevenet, 2020, BMC Medical Research Methodology.

Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

W. Chung, D. Steinemann, F. Couch, 2022, Communications Biology.

Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma.

J. Blay, C. Bain, M. Favrot, 1997, British Journal of Cancer.

High-dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin's lymphoma.

P. Biron, F. Chauvin, C. Lasset, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

French women’s breast self-examination practices with time after undergoing BRCA1/2 genetic testing

C. Maheu, T. Apostolidis, C. Lasset, 2012, Familial Cancer.

Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics

J. Fricker, L. Faivre, A. Bouhnik, 2010, Genetics in Medicine.

Prospective multicentric study of the etiology of 1051 bacteremic episodes in 782 cancer patients

C. Lasset, P. Auwera, M. Viot, 2004, Supportive Care in Cancer.

First estimates of diffuse gastric cancer risks for carriers of CTNNA1 germline pathogenic variants

Y. Drouet, D. Stoppa-Lyonnet, B. Buecher, 2022, Journal of Medical Genetics.

Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial

J. Blay, A. Viari, I. Treilleux, 2022, Journal of personalized medicine.

[Li-Fraumeni syndrome: update, new data and guidelines for clinical management].

O. Delattre, D. Frappaz, C. Bonaiti-Pellié, 2001, Bulletin du cancer.

High-dose consolidation chemotherapy in infants with stage 4 neuroblastoma. The European Group for Bone Marrow Transplantation.

C. Lasset, T. Philip, R. Ladenstein, 1993, European journal of cancer.

Multivariate analysis of prognostic factors in patients with non HIV-related primary cerebral lymphoma. A proposal for a prognostic scoring.

B. Coiffier, C. Gisselbrecht, F. Chauvin, 1993, British Journal of Cancer.

Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie

A. Ravaud, J. Douillard, C. Lasset, 2005, World Journal of Urology.

Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.

M. Stratton, M. J. van de Vijver, J. Chang-Claude, 1998, Journal of the National Cancer Institute.

Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease.

Edith Le Floch, P. Guénel, T. Truong, 2022, European journal of cancer.

Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK)

Elisabeth Cardis, Susan Peock, Joan Paterson, 2012, BMJ : British Medical Journal.

Neurofibromatosis and early onset of cancers in hMLH1-deficient children.

D. Frappaz, A. Puisieux, Q. Wang, 1999, Cancer research.

Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers.

J. Simard, D. Yannoukakos, J. Peyrat, 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Common BRCA 2 Variants and Modification of Breast and Ovarian Cancer Risk in BRCA 1 Mutation Carriers

J. Simard, D. Yannoukakos, J. Peyrat, 2005 .

The Lyon and the Ebmt Data On Megatherapy (Mgt) in Neuroblastoma Followed by Bone-Marrow Rescue

G. Dini, T. Klingebiel, J. Zucker, 1992 .

[Interleukin-2 and interferon in metastatic kidney cancer. Experience of the French Immunotherapy Group].

J. Douillard, C. Lasset, C. Chevreau, 2002, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Disparities of Perceptions and Practices Related to Cervical Cancer Prevention and the Acceptability of HPV Vaccination According to Educational Level in a French Cross-Sectional Survey of 18–65 Years Old Women

P. Vanhems, F. Chauvin, C. Lasset, 2014, PloS one.

Advances in Brief Neurofibromatosis and Early Onset of Cancers in h MLH 1-deficient Children 1

D. Frappaz, A. Puisieux, Qing Wang, 1999 .

Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: report from the European Group for Bone Marrow Transplantation.

S. Burdach, T. Klingebiel, F. Chauvin, 1994, Bone marrow transplantation.

BRCA1/2 carriers: their childbearing plans and theoretical intentions about having preimplantation genetic diagnosis and prenatal diagnosis

D. Stoppa-Lyonnet, L. Faivre, A. Bouhnik, 2012, Genetics in Medicine.

Targeted Sequencing of the Mitochondrial Genome of Women at High Risk of Breast Cancer without Detectable Mutations in BRCA1/2

G. Thomas, D. Cox, D. Stoppa-Lyonnet, 2015, PloS one.

Medulloblastoma in adults: survival and prognostic factors.

J. Blay, E. Bouffet, C. Lasset, 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer

J. Blay, V. Grégoire, B. Fervers, 2021, ESMO open.

Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.

Stefania Tommasi, Laura Cortesi, Mads Thomassen, 2019, Cancer research.

Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

D. Steinemann, F. Couch, B. Bonanni, 2020, Genetics in Medicine.

Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes

P. Chappuis, I. Treilleux, O. Trédan, 2020, Scientific Reports.

Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer

Michael Jones, Peter Kraft, Arnaud Droit, 2017, Nature Genetics.

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus

A. Whittemore, L. Kiemeney, S. Cross, 2016, Nature Communications.

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

R. Nussbaum, D. Steinemann, F. Couch, 2016, Breast Cancer Research.

Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

J. S. Hoffman, W. Chung, V. Pankratz, 2012, Human mutation.

CD44--a new prognostic marker for neuroblastoma.

V. Combaret, M. Favrot, C. Lasset, 1993, The New England journal of medicine.

Impact of megatherapy on survival after relapse from stage 4 neuroblastoma in patients over 1 year of age at diagnosis: a report from the European Group for Bone Marrow Transplantation.

D. Frappaz, S. Burdach, T. Klingebiel, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype

N. Voirin, D. Cox, I. Treilleux, 2009, British Journal of Cancer.

Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach.

F. Révillion, R. Lidereau, N. Sevenet, 2021, American journal of human genetics.

Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women

Olufunmilayo I. Olopade, Mads Thomassen, Dieter Niederacher, 2016, Breast Cancer Research.

Bibliometric analysis of a century of research on oral erythroplakia and leukoplakia

P. Saintigny, C. Lasset, D. Pérol, 2018, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2019, Nature Genetics.

Variants in the netrin-1 receptor UNC5C prevent apoptosis and increase risk of familial colorectal cancer.

L. Aaltonen, Y. Drouet, S. Liyanarachchi, 2011, Gastroenterology.

National recommendations of the French Genetics and Cancer Group - Unicancer on the modalities of multi-genes panel analyses in hereditary predispositions to tumors of the digestive tract.

B. Buecher, C. Lasset, P. Berthet, 2020, European journal of medical genetics.

University of Groningen Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk Couch,

F. Couch, B. Bonanni, O. Olopade, 2013 .

Gene‐ and pathway‐level analyses of iCOGS variants highlight novel signaling pathways underlying familial breast cancer susceptibility

E. Barillot, P. Guénel, T. Truong, 2020, International journal of cancer.

Mutation analysis of PALB2 gene in French breast cancer families

D. Stoppa-Lyonnet, O. Sinilnikova, S. Mazoyer, 2015, Breast Cancer Research and Treatment.

RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.

F. Couch, O. Olopade, T. Rebbeck, 2007, American journal of human genetics.

Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes

Y. Drouet, S. Boyault, Qing Wang, 2012, Breast Cancer Research and Treatment.

Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry.

D. Frappaz, T. Klingebiel, F. Chauvin, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.

Mads Thomassen, Nina Ditsch, Muhammad Usman Rashid, 2015, JAMA.

Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.

Laetitia Huiart, Dominique Leroux, Bernard Bonaïti, 2011, JAMA.

Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutation

D. Stoppa-Lyonnet, S. Mazoyer, F. Damiola, 2021, Breast cancer research : BCR.

Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study.

Katherine M. Tucker, W. Chung, R. Nussbaum, 2018, Journal of the National Cancer Institute.

Contribution of BRCA1 and BRCA2 germ‐line mutations to the incidence of breast cancer in young women: Results from a prospective population‐based study in France

D. Easton, A. Antoniou, G. Lenoir, 2005, Genes, chromosomes & cancer.

[Inherited predisposition to breast cancer: after the BRCA1 and BRCA2 genes, what next?].

C. Lasset, V. Bonadona, 2003, Bulletin du cancer.

Effects of genetic consultation on perception of a family risk of breast/ovarian cancer and determinants of inaccurate perception after the consultation.

D. Stoppa-Lyonnet, L. Huiart, H. Sobol, 2002, Journal of clinical epidemiology.

Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie.

J. Blay, A. Ravaud, J. Douillard, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie.

A. Ravaud, J. Douillard, B. Escudier, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study

R. Eeles, J. Hopper, D. Easton, 2021, American journal of obstetrics and gynecology.

Transmission of germline TP53 mutations from male carriers to female partners

T. Frebourg, C. Lasset, G. Bougeard, 2015, Journal of Medical Genetics.

Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores

D. Steinemann, F. Couch, O. Olopade, 2017, Journal of Clinical Oncology.

Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients.

J. Blay, F. Chauvin, C. Lasset, 1993, British Journal of Cancer.

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.

A. Ravaud, J. Douillard, T. Tursz, 1998, The New England journal of medicine.

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2021, Nature Communications.

Germline copy number variation of genes involved in chromatin remodelling in families suggestive of Li-Fraumeni syndrome with brain tumours

Z. Herceg, T. Frebourg, C. Férec, 2013, European Journal of Human Genetics.

Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review

N. Voirin, G. Lenoir, I. Treilleux, 2006, Breast Cancer Research and Treatment.

TUMOSPEC: A Nation-Wide Study of Hereditary Breast and Ovarian Cancer Families with a Predicted Pathogenic Variant Identified through Multigene Panel Testing

J. Lemonnier, N. Sevenet, D. Stoppa-Lyonnet, 2021, Cancers.

Age-Dependent Cancer Risk Is Not Different in between MSH2 and MLH1 Mutation Carriers

P. Hutter, G. Thomas, Kai Yu, 2009, Journal of cancer epidemiology.

Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium

J. Hopper, E. John, D. Easton, 2019, Cancer Epidemiology, Biomarkers & Prevention.

Variation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French National BRCA1/2 carrier cohort (GENEPSO)

R. Lidereau, D. Stoppa-Lyonnet, J. Fricker, 2011, Breast Cancer Research and Treatment.

The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

W. Chung, F. Couch, O. Olopade, 2021, Genetics in Medicine.

Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.

Christiana Kartsonaki, Mads Thomassen, Etienne Rouleau, 2011, Human molecular genetics.

Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO)

R. Lidereau, D. Stoppa-Lyonnet, P. Pujol, 2012, Breast Cancer Research.

Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape.

J. Rossi, A. Ravaud, J. Douillard, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1/2 carrier cohort (GENEPSO).

R. Lidereau, D. Stoppa-Lyonnet, P. Pujol, 2018 .

GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers

D. Stoppa-Lyonnet, S. Mazoyer, C. Houdayer, 2018, Front. Oncol..

Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests

D. Khayat, R. Lidereau, M. Picot, 2013, Breast Cancer Research and Treatment.

Parental disclosure of positive BRCA1/2 mutation status to children 10 years after genetic testing

D. Stoppa-Lyonnet, R. Touzani, J. Mancini, 2020, Psychology, health & medicine.

GENESIS: a French national resource to study the missing heritability of breast cancer

D. Stoppa-Lyonnet, O. Sinilnikova, S. Mazoyer, 2016, BMC Cancer.

An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

W. Chung, R. Nussbaum, D. Steinemann, 2015, Breast Cancer Research.

Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers

W. Chung, R. Nussbaum, D. Steinemann, 2015, PloS one.

phylogenetic approach identified mitochondrial haplogroup T 1 a 1 as inversely associated with breast cancer risk in BRCA 2 mutation carriers

W. Chung, D. Steinemann, V. Pankratz, 2015 .

Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.

F. Couch, T. Rebbeck, J. Benítez, 2011, Human molecular genetics.

Indication and limits of megatherapy and bone marrow transplantation in high-risk neuroblastoma: a single centre analysis of prognostic factors.

P. Biron, V. Combaret, F. Chauvin, 1993, European journal of cancer.

Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma

A. Ravaud, J. Douillard, T. Tursz, 1998 .

LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis.

D. Frappaz, V. Combaret, J. Stéphan, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BRCA2 Deep Intronic Mutation Causing Activation of a Cryptic Exon: Opening toward a New Preventive Therapeutic Strategy

Olga Anczuków, O. Sinilnikova, S. Mazoyer, 2012, Clinical Cancer Research.

Is neuroblastoma screening evaluation needed and feasible?

D. Frappaz, L. Parker, F. Herrmann, 1995, British Journal of Cancer.

Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study.

Katherine M. Tucker, Aung Ko Win, Swati G. Patel, 2021, The Lancet. Oncology.

Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene

V. Gaborieau, D. Yannoukakos, J. Peyrat, 2005, International journal of cancer.

Publisher Correction: Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes

P. Chappuis, I. Treilleux, O. Trédan, 2020, Scientific Reports.

Metastatic medulloblastoma: the experience of the French Cooperative M7 Group.

E. Bouffet, C. Lasset, F. Doz, 1994, European journal of cancer.

Human papillomavirus (HPV) vaccination: perception and practice among French general practitioners in the year since licensing.

P. Vanhems, F. Chauvin, C. Lasset, 2011, Vaccine.

Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT Solid Tumour Registry.

S. Burdach, C. Lasset, C. Peters, 1995, Bone marrow transplantation.

Anti-müllerian hormone levels and antral follicle count in women with a BRCA1 or BRCA2 germline pathogenic variant: A retrospective cohort study

Y. Drouet, C. Rousset-Jablonski, N. Chopin, 2021, Breast.

Acetyl-CoA carboxylase alpha gene and breast cancer susceptibility.

Olga Anczuków, D. Thompson, G. Lenoir, 2004, Carcinogenesis.

Estimating cancer risk in HNPCC by the GRL method

H. Perdry, C. Bonaïti‐pellié, Qing Wang, 2007, European Journal of Human Genetics.

Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 genes in 75 French kindreds with nonpolyposis colorectal cancer

J. Saurin, J. Bosset, A. Puisieux, 1999, Human Genetics.

Cancer patients who experienced diagnostic genetic testing for cancer susceptibility: reactions and behavior after the disclosure of a positive test result.

J. Saurin, O. Sinilnikova, A. Puisieux, 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Impact of an information booklet on satisfaction and decision-making about BRCA genetic testing.

D. Stoppa-Lyonnet, A. Chompret, J. Fricker, 2006, European journal of cancer.

[Prognostic factors in the response of a first line chemotherapy in advanced breast cancer].

F. Chauvin, C. Lasset, J. Jacquin, 1990, Bulletin du cancer.

Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec

J. Simard, M. Dorval, C. Lasset, 2011, European Journal of Human Genetics.

Evaluation of CD44 prognostic value in neuroblastoma: comparison with the other prognostic factors.

D. Frappaz, V. Combaret, R. Bouvier, 1995, European journal of cancer.

Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas.

D. Frappaz, V. Combaret, M. Favrot, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

“Maybe they have found something new” participants’ views on returning cohort psychosocial survey results

C. Lasset, C. Julian‐Reynier, C. Noguès, 2015, Health expectations : an international journal of public participation in health care and health policy.

[Value of C-reactive protein determination in small cell lung cancer].

P. Souquet, C. Lasset, J. Cordier, 1993, Bulletin du cancer.

Factors associated with Pap smear screening among French women visiting a general practitioner in the Rhône-Alpes region.

C. Lasset, J. Haesebaert, D. Lutringer-Magnin, 2013, Revue d'epidemiologie et de sante publique.

[Adjuvant therapy of breast cancer with tamoxifen and endometrial carcinoma].

A. Sasco, C. Lasset, M. Rivoire, 1992, Bulletin du Cancer.

Clinical relevance of TRKA expression on neuroblastoma: comparison with N-MYC amplification and CD44 expression.

D. Frappaz, V. Combaret, R. Bouvier, 1997, British Journal of Cancer.

Is There a Demand for PGD and/or PND Among Healthy BRCA1/2 Carriers at a Reproductive Age? A Contingent Valuation Survey.

D. Stoppa-Lyonnet, C. Protière, E. Mouret‐Fourme, 2014 .

Prevention of sexually transmitted infections among girls and young women in relation to their HPV vaccination status.

P. Vanhems, F. Chauvin, C. Lasset, 2013, European journal of public health.

Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium

E. John, M. Southey, D. Easton, 2023, Breast Cancer Research.

Disclosure of research results: a randomized study on GENEPSO‐PS cohort participants

J. Mancini, A. Bouhnik, N. Resseguier, 2015, Health expectations : an international journal of public participation in health care and health policy.

Small-cell lung cancer: patients included in clinical trials are not representative of the patient population as a whole.

V. Cottin, F. Chauvin, C. Lasset, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Cigarette smoking in women after BRCA1/2 genetic test disclosure: a 5-year follow-up study of the GENEPSO PS cohort

A. Bouhnik, N. Resseguier, C. Lasset, 2014, Genetics in Medicine.

[Ovarian cancer epidemiology].

C. Lasset, 1995, Soins; la revue de reference infirmiere.

Management of patients diagnosed with atypical ductal hyperplasia by vacuum-assisted core biopsy: a prospective assessment of the guidelines used at our institution.

Y. Drouet, I. Treilleux, C. Chassagne‐Clément, 2014, American journal of surgery.

Screening for neuroblastoma in France: methodological aspects and preliminary observations.

D. Frappaz, J. Estève, V. Combaret, 1997, Medical and pediatric oncology.

HPV vaccination among French girls and women aged 14-23 years and the relationship with their mothers' uptake of Pap smear screening: a study in general practice.

P. Vanhems, F. Chauvin, C. Lasset, 2013, Vaccine.

Overview of the Genetic Causes of Hereditary Breast and Ovarian Cancer Syndrome in a Large French Patient Cohort

C. Lasset, A. Calender, M. Léoné, 2023, Cancers.

Multicentric Phase II Study of Cisplatin and Etoposide in Patients With Metastatic Carcinoma of Unknown Primary

C. Lasset, Y. Merrouche, S. Négrier, 2000, American journal of clinical oncology.

Focus group approach for developing written patient information in oncogenetics.

C. Lasset, V. Bonadona, M. Charavel, 2007, Genetic testing.

The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2.

M. Stratton, M. J. van de Vijver, J. Chang-Claude, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Molecular basis of the Li–Fraumeni syndrome: an update from the French LFS families

C. Bonaïti‐pellié, D. Stoppa-Lyonnet, A. Chompret, 2008, Journal of Medical Genetics.

Acceptability of prophylactic mastectomy in cancer-prone women.

D. Stoppa-Lyonnet, H. Sobol, C. Lasset, 2000, JAMA.

Multivariate analysis of prognostic factors in patients with non HIV-related primary cerebral lymphoma. A proposal for a prognostic scoring.

B. Coiffier, C. Gisselbrecht, F. Chauvin, 1993, British Journal of Cancer.

[The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].

P. Pujol, C. Lasset, P. Berthet, 2018, Bulletin du cancer.

Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK)

David Evans, R. Eeles, D. Easton, 2012, BMJ.

Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK)

David Evans, R. Eeles, D. Easton, 2012, British medical journal.